5nQ

5nQ is a Swiss biotechnology company specializing in structure-based drug discovery for G protein-coupled receptors (GPCRs), a critical class of therapeutic targets. The company utilizes a proprietary platform to stabilize these notoriously unstable membrane proteins in specific, pharmacologically relevant conformations. This stabilization enables high-resolution structural analysis using X-ray crystallography and cryo-electron microscopy, which is essential for precise drug design. By focusing on challenging or previously "undruggable" GPCR targets, 5nQ aims to identify novel small molecule leads with superior selectivity and potency. The company is a spin-off from the Paul Scherrer Institute (PSI) and leverages deep expertise in structural biology to accelerate the development of next-generation medicines. 5nQ's approach integrates advanced protein engineering with computational chemistry to bridge the gap between target identification and lead optimization.